Teva and Samsung Bioepis announced a license and commercialization agreement for OPUVIZ in Canada. The deal expands Teva’s commercial footprint for the product and supports incremental revenue potential, though no financial terms were disclosed in the report.
Teva and Samsung Bioepis announced a license and commercialization agreement for OPUVIZ in Canada. The deal expands Teva’s commercial footprint for the product and supports incremental revenue potential, though no financial terms were disclosed in the report.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.12
Ticker Sentiment
